Preprint Review Version 6 Preserved in Portico This version is not peer-reviewed

Discovery and Development of Safe-in-Man Broad-Spectrum Antiviral Agents

Version 1 : Received: 12 October 2019 / Approved: 13 October 2019 / Online: 13 October 2019 (15:22:27 CEST)
Version 2 : Received: 7 November 2019 / Approved: 7 November 2019 / Online: 7 November 2019 (14:59:43 CET)
Version 3 : Received: 26 December 2019 / Approved: 27 December 2019 / Online: 27 December 2019 (03:35:32 CET)
Version 4 : Received: 27 January 2020 / Approved: 27 January 2020 / Online: 27 January 2020 (02:09:09 CET)
Version 5 : Received: 7 February 2020 / Approved: 10 February 2020 / Online: 10 February 2020 (09:55:44 CET)
Version 6 : Received: 12 February 2020 / Approved: 14 February 2020 / Online: 14 February 2020 (02:27:24 CET)

How to cite: Andersen, P.I.; Ianevski, A.; Lysvand, H.; Vitkauskiene, A.; Oksenych, V.; Bjoras, M.; Telling, K.; Lutsar, I.; Dumpis, U.; Irie, Y.; Tenson, T.; Kantele, A.; Kainov, D.E. Discovery and Development of Safe-in-Man Broad-Spectrum Antiviral Agents. Preprints 2019, 2019100144 (doi: 10.20944/preprints201910.0144.v6). Andersen, P.I.; Ianevski, A.; Lysvand, H.; Vitkauskiene, A.; Oksenych, V.; Bjoras, M.; Telling, K.; Lutsar, I.; Dumpis, U.; Irie, Y.; Tenson, T.; Kantele, A.; Kainov, D.E. Discovery and Development of Safe-in-Man Broad-Spectrum Antiviral Agents. Preprints 2019, 2019100144 (doi: 10.20944/preprints201910.0144.v6).

Abstract

Viral diseases are one of the leading causes of morbidity and mortality in the world. Virus-specific vaccines and antiviral drugs are the most powerful tools to combat viral diseases. However, broad-spectrum antiviral agents (BSAAs, i.e. compounds targeting viruses belonging to two or more viral families) could provide additional protection of general population from emerging and re-emerging viral diseases reinforcing the arsenal of available antiviral options. Here, we reviewed discovery and development of BSAAs and summarized the information on 120 safe-in-man agents in freely accessible database (https://drugvirus.info/). Future and ongoing pre-clinical and clinical studies will increase the number of BSAAs, expand spectrum of their indications, and identify drug combinations for treatment of emerging and re-emerging viral infections as well as co-infections.

Subject Areas

virus; antiviral drug; drug discovery; drug development; broad-spectrum antivirals

Comments (1)

Comment 1
Received: 14 February 2020
Commenter: Denis Kainov
Commenter's Conflict of Interests: Author
Comment: accepted manuscript
+ Respond to this comment

We encourage comments and feedback from a broad range of readers. See criteria for comments and our diversity statement.

Leave a public comment
Send a private comment to the author(s)
Views 0
Downloads 0
Comments 1
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.